Inflammation and muscle weakness in COPD: Considering a renewed role for Theophylline?

Allen, S., Khattab, A. D., Vassallo, M. and Kwan, J., 2018. Inflammation and muscle weakness in COPD: Considering a renewed role for Theophylline? Current Respiratory Medicine Reviews, 14 (1), 35 - 41.

Full text available as:

[img] PDF
Allen et al Theophylline COPD inflammation-final acepted version.pdf - Accepted Version
Restricted to Repository staff only until 22 May 2019.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

202kB

DOI: 10.2174/1573398X14666180525113544

Abstract

© 2018 Bentham Science Publishers. Background: The methyl-xanthine drug theophylline has been used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) for several decades. Phosphodiesterase inhibition leading to smooth muscle relaxation is its main mode of action as a broncho-dilating agent, requiring blood theophylline concentrations close to the toxic range and a consequent problem with side effects. It also has anti-inflammatory effects that occur at relatively low concentrations. Objective: To explore supporting evidence for how other properties of theophylline could be of considerable clinical utility, particularly in reducing weakness and overt sarcopenia, based on its antiinflammatory, steroid-sparing and immune-modulating properties. Methods: PUBMED and MEDLINE were scanned using the search terms: theophylline, antiinflammatory, cytokine, inflammation, ageing, sarcopenia, frailty, chronic obstructive airways disease, pulmonary rehabilitation. High quality articles were selected, read in-depth and discussed by the authors, then used as the basis for a proposition on the potential anti-inflammatory and antisarcopenic use of theophylline. Findings: The anti-inflammatory properties of theophylline are mainly mediated by histone deacetylase induction in immune competent cells with a resulting shift toward the expression of a less inflamed phenotype, including a reduction of the release of pro-inflammatory cytokines and the associated increase in anti-inflammatory cytokines. These effects occur at blood theophylline concentrations well below the range for direct broncho-dilatation. Conclusion: There are potential therapeutic benefits of theophylline that are systemic and not confined to airways inflammation in COPD. There is scope for a beneficial effect in other chronic inflammatory states and post-acute inflammation with slow resolution. There is compelling evidence that theophylline could be used for anti-inflammatory adjunctive treatment to improve independent function, muscle strength and other outcomes in individuals recovering from acute inflammatory episodes, including but not limited to exacerbations of COPD, and as a pharmaceutical intervention in support of pulmonary rehabilitation.

Item Type:Article
ISSN:1573-398X
Uncontrolled Keywords:Chronic obstructive pulmonary disease; illness behaviour; immune modulation; pulmonary rehabilitation; sarcopenia; systemic inflammation; theophylline
Group:Faculty of Health & Social Sciences
ID Code:31102
Deposited By: Unnamed user with email symplectic@symplectic
Deposited On:06 Aug 2018 11:00
Last Modified:06 Aug 2018 11:00

Downloads

Downloads per month over past year

More statistics for this item...
Repository Staff Only -